Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 10
- Registration Number
- NCT06731504
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Leland Metheny
- Target Recruit Count
- 20
- Registration Number
- NCT06680661
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Duke University
- Target Recruit Count
- 400
- Registration Number
- NCT06654882
A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20000
- Registration Number
- NCT06418529
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06279494
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
- Conditions
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 92
- Registration Number
- NCT05621759
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05451615
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 20
- Registration Number
- NCT05426252
- Locations
- 🇨🇦
Yogi Chopra, Toronto, Ontario, Canada
High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT) Study
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 74
- Registration Number
- NCT05289167
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
COVID-19 VaccinE Response in Rheumatology Patients
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Jeffrey Curtis
- Target Recruit Count
- 1000
- Registration Number
- NCT05080218
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
🇺🇸University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.